Your browser doesn't support javascript.
loading
Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice.
Schmid, Anna Marlene; Razim, Agnieszka; Wysmolek, Magdalena; Kerekes, Daniela; Haunstetter, Melissa; Kohl, Paul; Brazhnikov, Georgii; Geissler, Nora; Thaler, Michael; Krcmárová, Eliska; Sindelár, Martin; Weinmayer, Tamara; Hrdý, Jirí; Schmidt, Katy; Nejsum, Peter; Whitehead, Bradley; Palmfeldt, Johan; Schild, Stefan; Inic-Kanada, Aleksandra; Wiedermann, Ursula; Schabussova, Irma.
Afiliación
  • Schmid AM; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090, Vienna, Austria.
  • Razim A; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090, Vienna, Austria.
  • Wysmolek M; Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
  • Kerekes D; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090, Vienna, Austria.
  • Haunstetter M; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090, Vienna, Austria.
  • Kohl P; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090, Vienna, Austria.
  • Brazhnikov G; Institute of Molecular Biosciences, Karl-Franzens-University, Graz, Austria.
  • Geissler N; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090, Vienna, Austria.
  • Thaler M; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090, Vienna, Austria.
  • Krcmárová E; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090, Vienna, Austria.
  • Sindelár M; Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic.
  • Weinmayer T; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
  • Hrdý J; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090, Vienna, Austria.
  • Schmidt K; Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic.
  • Nejsum P; Core Facility for Cell Imaging and Ultrastructural Research, Faculty of Life Sciences, University of Vienna, Vienna, Austria.
  • Whitehead B; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Palmfeldt J; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Schild S; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Inic-Kanada A; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Wiedermann U; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Schabussova I; Institute of Molecular Biosciences, Karl-Franzens-University, Graz, Austria.
Cell Commun Signal ; 21(1): 297, 2023 10 20.
Article en En | MEDLINE | ID: mdl-37864211
BACKGROUND: E. coli O83 (Colinfant Newborn) is a Gram-negative (G-) probiotic bacterium used in the clinic. When administered orally, it reduces allergic sensitisation but not allergic asthma. Intranasal administration offers a non-invasive and convenient delivery method. This route bypasses the gastrointestinal tract and provides direct access to the airways, which are the target of asthma prevention. G- bacteria such as E. coli O83 release outer membrane vesicles (OMVs) to communicate with the environment. Here we investigate whether intranasally administered E. coli O83 OMVs (EcO83-OMVs) can reduce allergic airway inflammation in mice. METHODS: EcO83-OMVs were isolated by ultracentrifugation and characterised their number, morphology (shape and size), composition (proteins and lipopolysaccharide; LPS), recognition by innate receptors (using transfected HEK293 cells) and immunomodulatory potential (in naïve splenocytes and bone marrow-derived dendritic cells; BMDCs). Their allergy-preventive effect was investigated in a mouse model of ovalbumin-induced allergic airway inflammation. RESULTS: EcO83-OMVs are spherical nanoparticles with a size of about 110 nm. They contain LPS and protein cargo. We identified a total of 1120 proteins, 136 of which were enriched in OMVs compared to parent bacteria. Proteins from the flagellum dominated. OMVs activated the pattern recognition receptors TLR2/4/5 as well as NOD1 and NOD2. EcO83-OMVs induced the production of pro- and anti-inflammatory cytokines in splenocytes and BMDCs. Intranasal administration of EcO83-OMVs inhibited airway hyperresponsiveness, and decreased airway eosinophilia, Th2 cytokine production and mucus secretion. CONCLUSIONS: We demonstrate for the first time that intranasally administered OMVs from probiotic G- bacteria have an anti-allergic effect. Our study highlights the advantages of OMVs as a safe platform for the prophylactic treatment of allergy. Video Abstract.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Probióticos / Vesículas Extracelulares / Hipersensibilidad Límite: Animals / Humans Idioma: En Revista: Cell Commun Signal Año: 2023 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Probióticos / Vesículas Extracelulares / Hipersensibilidad Límite: Animals / Humans Idioma: En Revista: Cell Commun Signal Año: 2023 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Reino Unido